• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Sagent Recalls Four Lots of Levetiracetam


The antiseizure medication affected by the recall could have sterility issues.

Sagent Pharmaceuticals is recalling four lots of Levetiracetam Injection, which is used for the treatment of certain types of seizures. It is packaged in a 5 mL single-does vial and was distributed from March 2021 until November 2021.

The recall is because of a lack of container closure integrity, which could lead to sterility issues. To date, Sagent has not received reports of any product complaints or adverse events associated with this issue.

The NDC number of the affected product is 25021-780-05. The lot numbers included in the recall include:

  • B0G85VB, with an expiration date of June 2022
  • B0K88VA, with an expiration date of September 2022
  • B0K89VA, with an expiration date of September 2022
  • B1G194A, with an expiration date of June 2023

Levetiracetam label

Levetiracetam label

© 2024 MJH Life Sciences

All rights reserved.